-
ACLA Response to WSJ’s Op-Ed on The High Cost of Constant Covid Testing
The following is ACLA’s submitted response to the Wall Street Journal’s June 6, 2022 op-ed on the high cost of constant COVID-19 testing. The June 6 ... Read More -
ACLA Comments on the VALID Act of 2022
-
Stakeholder letter to Secretary Becerra Urging HHS to Extend the COVID-19 Public Health Emergency
-
COVID-19 Uninsured Relief Fund Joint Letter
-
COVID Relief Funding Letter
-
PREVENT Pandemics Act Discussion Draft ACLA Comment Letter
-
ACLA Response to the New York Times’ Article on NIPT
The following is ACLA’s submitted response to the New York Times’ January 1, 2022 Article on Non-Invasive Prenatal Testing (NIPT). The Times’ Jan. 1 article presents a ... Read More -
Letter from Industry Stakeholders on Protecting Seniors’ Access to Lab Tests
-
ACLA COMMENTS ON 2022 ONC INTEROPERABILITY STANDARDS ADVISORY (ISA)
-
ACLA, AdvaMedDx Letter to COVID-19 Response Team
